ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

1.46
-0.07
(-4.58%)
Closed April 15 4:00PM
1.44
-0.02
(-1.37%)
After Hours: 7:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.651.651.071.150.000.00 %032-
1.000.400.600.520.500.024.00 %27834/12/2024
1.500.050.100.100.0750.000.00 %1013,1484/12/2024
2.000.020.050.020.0350.000.00 %2376,9934/12/2024
2.500.040.050.040.0450.000.00 %015,253-
5.000.030.050.030.040.000.00 %14,9404/12/2024

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.020.050.020.0350.000.00 %01,106-
1.000.050.050.010.05-0.04-80.00 %7019,0814/12/2024
1.500.100.150.100.1250.000.00 %1,1378,5864/12/2024
2.000.450.550.550.500.1022.22 %474,9924/12/2024
2.501.001.051.051.0250.1516.67 %5261,5824/12/2024
5.003.403.603.003.500.000.00 %02-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
MNDRMobile health Network Solutions
$ 14.87
(45.78%)
10.66M
CNXAConnexa Sports Technologies Inc
$ 1.50
(38.89%)
16.88M
PRZOParaZero Technologies Ltd
$ 1.08
(38.46%)
12.94M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
MOTSMotus GI Holdings Inc
$ 0.2631
(-37.76%)
1.79M
CISSC3is Inc
$ 1.865
(-35.24%)
5.7M
LXEHLixiang Education Holding Company Ltd
$ 0.4325
(-33.46%)
3.12M
GVHGlobavend Holdings Ltd
$ 1.20
(-29.82%)
227.4k
SLNHSoluna Holdings Inc
$ 1.59
(-28.05%)
423.89k
SQQQProShares UltraPro Short QQQ
$ 10.89
(4.71%)
176.08M
NKLANikola Corporation
$ 0.7014
(-2.18%)
134.38M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
AAPLApple Inc
$ 176.55
(0.86%)
101.67M

AKBA Discussion

View Posts
ErnieBilco ErnieBilco 2 weeks ago
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 2 weeks ago
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 2 weeks ago
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 2 weeks ago
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 2 weeks ago
Long solid position here!
👍️0
Limey42 Limey42 3 weeks ago
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 3 weeks ago
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 3 weeks ago
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 3 weeks ago
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 3 weeks ago
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 weeks ago
AKBA new 52 hi
👍️0
eyeownu eyeownu 3 weeks ago
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 4 weeks ago
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 1 month ago
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 1 month ago
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 1 month ago
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 1 month ago
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 2 months ago
$AKBA
👍️0
eyeownu eyeownu 2 months ago
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 2 months ago
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 2 months ago
$AKBA profit taking! hope you took some off the table!
👍️0
eyeownu eyeownu 3 months ago
PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

What percentage of PDUFA are approved?
Characteristic Percentage of drugs approved in 2023
Met PDUFA goal date* 89%
First cycle of review 84%
Approved in the United States before receiving approval in any other country 64%
Priority review 56%

From
👍️0
eyeownu eyeownu 3 months ago
$AKBA via stocktwit @Bidzill @fresh10 fresh - We have PDUFA date scheduled for March 27, 2024 concerning Vadadustat DD USA. Approval is de-risked and highly likely, IMO. We have product launch date first half of year for Vadadustat DD EU/Australia. We have phase 2 trial for AKB 9090 for second half of 2024. We have Auryxia all time/near all time high sales 2024. Good luck 🍀 to you and us.
👍️0
eyeownu eyeownu 3 months ago
https://www.tradingview.com/x/6Ykwijbc/
👍️0
eyeownu eyeownu 3 months ago
$AKBA from stocktwits

MORE GOOD NEWS - FDA Fast Track Designation is process designed to facilitate development & expedite drug review to treat serious conditions & fill UNMET MEDICAL NEED. Determining whether condition is serious enough for designation is matter of judgment … ARDS is life threatening & acute, diffuse, inflammatory form of lung injury in seriously ill patients characterized by poor oxygenation, pulmonary infiltrates, acute onset. Unadjusted hospitalization mortality was reported to be 35% among those w/ mild ARDS, 40% w/ moderate disease, 46% for patients w/ severe ARDS. AKB 9090 is Akebia’s ARDS drug. Filling an unmet need is defined as providing therapy where none exists or which may be potentially better than available therapy. Drug that receives Fast Track is eligible for accelerated approval/priority review. August of 2022, CEO Butler said Vadadustat was in trials for Covid-19/ARDS which was an “unmet medical need.” Butler was signaling intention to go after Fast Track status.
https://stocktwits.com/buythehornz127/message/559186953
👍️0
eyeownu eyeownu 3 months ago
John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 Annual J.P. Morgan
Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023. Spokespersons of the Company also plan
to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference

https://ir.akebia.com/static-files/0be66d7f-9988-43fa-bcab-e587260e1dc0
👍️0
eyeownu eyeownu 3 months ago
easy money https://schrts.co/JdqbEsCN wait till the real news drops!
👍️0
eyeownu eyeownu 3 months ago
$AKBA shabba https://schrts.co/bYSHjBzF
👍️0
eyeownu eyeownu 3 months ago
this is looking good. if the RSI ever resets i'm going all in!
👍️0
eyeownu eyeownu 4 months ago
end of year. double top forming or is it slow and steady?
👍️0
glenn1919 glenn1919 8 months ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
AKBA full out weekly trend in place
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
AKBA MONSTER BREAK OUT
👍️0
glenn1919 glenn1919 9 months ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
here we go...break out!!!
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AKBA IN PLAY...WEEKLY SETTING UP FOR A BIG POP!!!
👍️ 1
tw0122 tw0122 11 months ago
Nice hits premarket
👍️0
Invest-in-America Invest-in-America 11 months ago
AKBA: Might Close today way UP, behind that news!!
👍️0
tw0122 tw0122 12 months ago
Nice rise from .50s past few weeks. Pump over??
4/25 news Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Source: PR Newswire (US)
CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Vadadustat is now approved in 32 countries.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

"We're extremely pleased the EC has approved Vafseo, an important milestone for Akebia but even more impactful for the hundreds of thousands of Europeans diagnosed with anaemia associated with CKD on dialysis," said John P. Butler, Chief Executive Officer of Akebia. "We believe patients receiving chronic maintenance dialysis would benefit from additional therapeutic options. With approval, we're eager to select a European partner who can quickly bring Vafseo to those patients."

Anemia associated with CKD, common in patients on dialysis, is a debilitating condition which may be associated with many adverse clinical outcomes. Vafseo, approved in 150 mg, 300 mg and 450 mg film-coated tablets, provides a once-daily oral treatment option for dialysis dependent patients with symptomatic anaemia associated with CKD. Throughout Europe, more than 200,000 dialysis patients are currently treated for anemia associated with CKD.

The approval follows the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) positive opinion issued in February 2023 recommending the EC approve Vafseo. The approval is based on data from a comprehensive development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis (INNO2VATE).

In the study of adult patients on dialysis, vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat also achieved the primary safety endpoint of the INNO2VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events, which is the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2VATE studies.

John Butler added, "We are grateful for the patients, physicians, investigators, and site coordinators who participated in our clinical trials that led to this important approval. I want to also express my deep appreciation for our team at Akebia as the approval is a culmination of years of work and a demonstration of their commitment to bettering the lives of people impacted by kidney disease."

👍️0
Afterhoursearnings3 Afterhoursearnings3 1 year ago
Bought a lot here today.
👍️0
shurtha2000 shurtha2000 1 year ago
two hedge funds competing to be largest AKBA stake holder AWESOME
👍️0
subslover subslover 1 year ago
Nice find G2G. :)
👍️0
TheFinalCD TheFinalCD 1 year ago
AKBA 2NEWS 2DAY

https://finance.yahoo.com/m/d467c3e1-c5b5-3419-8f7d-a3b3ad6ab3e4/the-petri-dish%3A-blindness.html

https://finance.yahoo.com/news/akebia-receives-positive-chmp-opinion-210500420.html

https://finviz.com/quote.ashx?t=AKBA&p=d
👍️0
Limey42 Limey42 1 year ago
Awesome news. Market cap of $136 million.....absolute joke!
👍️0
Limey42 Limey42 1 year ago
Panic selling because of that huge short position that just opened...bastardos
👍️0
willlbone willlbone 1 year ago
Panic selling.
👍️0
ANTADOG ANTADOG 1 year ago
1,05~~ ANT
👍️0
ANTADOG ANTADOG 1 year ago
touched one dollar pm, lookin' for volume again, ANT
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
AKBA...WHAT A BEAST
👍️0
ANTADOG ANTADOG 1 year ago
Avg daily volume is in and still more than 2 hours to go, will we break one buck on a Friday? ANT
👍️0

Your Recent History

Delayed Upgrade Clock